GE Healthcare to support Cellular Biomedicine Group's facility upgrade

Medical Company Product News

GE Healthcare has agreed to work with Cellular Biomedicine Group to accelerate its cell therapy manufacturing activities.

Taking advantage of GE Healthcare’s FlexFactory platform, Cellular Biomedicine Group will configure part of its facility in Shanghai to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch.

“GE Healthcare will be leveraging its FlexFactory platform to help Cellular Biomedicine Group to configure part of its facility in Shanghai.“

FlexFactory is a scalable, semi-automated end-to-end platform that can help to optimise a lab for industrial-scale manufacturing - a process that would typically take more than 18 months to complete, but can be reduced to nine months with this service.

Cellular Biomedicine Group will become the first company to install FlexFactory for cell therapy, with the site to be operational by the end of 2018. GE Healthcare will provide process development and training services, cell processing equipment, semi-automation capabilities, and digital connectivity solutions as part of this package.

Ger Brophy, general manager of cell therapy for GE Healthcare Life Sciences, said: "We are committed to collaborating with cell therapy manufacturers on their journey from trials to industrialisation, as they look to ultimately deliver these groundbreaking therapies to thousands of patients around the world."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news